That's crap and you know it. Of course, they have the results. These trials are under a collaboration agreement with UCSF.
Oct 19, 2004 UCSF And Insmed to Collaborate on Clinical Program in Prostate Cancer
o Insmed and UCSF will initiate a dose-escalating clinical study primarily designed to define the maximum tolerated dose of INSM-18 in patients with relapsed prostate cancer. The study will consist of a 28-day extension at each dose level to investigate the effect of INSM-18 on prostate specific antigen (PSA) levels. PSA is a standard serum marker for prostate cancer progression.
o INSM-18, a small molecule tyrosine kinase inhibitor, has demonstrated selective inhibition of the insulin-like growth factor-I receptor (IGF-I) and human epidermal growth factor receptor (Her2/neu). It has demonstrated anti-tumor activity in preclinical studies of breast, lung, pancreatic and prostate tumors. Two single dose Phase I clinical studies have been previously completed with INSM-18. In both studies, INSM-18 was safe and well tolerated.
o Dr. Allan “We are very excited to expand our pipeline with this novel tyrosine kinase inhibitor, utilizing our extensive knowledge in IGF biology and growth factor signalling. A small molecule approach could be very complimentary to our cancer program with rhIGFBP-3, our lead compound in this area, which has just entered Phase I clinical studies."